U.S. FDA approves Supernus' drug-device combination for Parkinson's disease
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
BioSpace1d
Supernus Taps Potential $300M US Opportunity With FDA Win for Parkinson’s Drug-Device Combo
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
FiercePharma1d
Supernus' 4th try proves the charm with long-awaited FDA approval for Parkinson's infusion pump Onapgo
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
The Pharma Letter15h
FDA nod at last for Supernus’ Parkinson’s infusion therapy
It is fourth time lucky for Supernus Pharmaceuticals, as its Parkinson’s specialist finally receives US approval for Onapgo ...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion ...
PMLiVE1d
FDA approves Supernus’ Onapgo to treat advanced Parkinson’s disease
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection ...
Supernus announces FDA approval of ONAPGO
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, approved ONAPGO injection, formerly known as ...
Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.
Supernus stock surges on FDA approval
The approval was based on a Phase 3 study showing significant reductions in daily OFF time and increases in GOOD ON time. Supernus CEO Jack Khattar expressed the company's commitment to developing ...
Supernus Pharmaceuticals exec sells shares worth $376,236
Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a company that InvestingPro data shows maintains ...
Supernus Pharmaceuticals, Inc.: Supernus Announces FDA Approval of ONAPGO (apomorphine hydrochloride) for Parkinson's Disease
ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion devi ...